<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">HALCINONIDE</span><br/>(hal-sin'oh-nide)<br/><span class="topboxtradename">Halog<br/></span><b>Classifications:</b> <span class="classification">skin and mucous membrane agent</span>; <span class="classification">antiinflammatory steroid</span><br/><b>Prototype: </b>Hydrocortisone<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.1% ointment, cream, solution; 0.025% cream</p>
<h1><a name="action">Actions</a></h1>
<p>Fluorinated steroid with substituted 17-hydroxyl group, chemically similar to flurandrenolide (Cordran).</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Crosses cell membranes, complexes with nuclear DNA and stimulates synthesis of enzymes thought to be responsible for antiinflammatory
         effects.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Relief of pruritic and inflammatory manifestations of corticosteroid-responsive dermatoses.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Use on large body surface area; long term use.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Children, lactation, pregnancy (category C).</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Inflammation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> Apply thin layer b.i.d. or t.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">Topical</span> Apply thin layer once/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Topical</span><br/><ul>
<li>Wash skin gently and dry thoroughly before each application.</li>
<li> 				Note: Ointment is preferred for dry scaly lesions. Moist lesions are best treated with solution. 			</li>
<li>Do not apply in or around the eyes.</li>
<li>Do not apply occlusive dressings over areas covered with halcinonide unless specifically prescribed.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Endocrine:</span> Reversible HPA axis suppression, hyperglycemia, glycosuria. <span class="typehead">Skin:</span> Burning, itching, irritation, erythema, dryness, folliculitis, hypertrichosis, pruritus, acneiform eruptions, hypopigmentation,
      perioral dermatitis, allergic contact dermatitis, stinging cracking/tightness of skin, secondary infection, skin atrophy,
      striae, miliaria, telangiectasia. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Minimum absorption through intact skin; increased absorption from axilla, eyelid, face, scalp, scrotum, or with occlusive
      dressing. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Discontinue if signs of infection or irritation occur.</li>
<li>Monitor for systemic corticosteroid effects that may occur with occlusive dressings or topical applications over large areas
            of skin.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not breast feed while using this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>